Trial intelligence / Profile preview

68Ga-NOTA-Anti-MMR-VHH2 PET/CT in Cardiac Sarcoidosis

2024-512473-27-00Phase 2Authorised

Sponsor: Cliniques universitaires Saint-Luc
Start: Sep 2024
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, open-label, single-arm trial of 68Ga-UZBRU-VHH2 in cardiac sarcoidosis (CS), sponsored by Cliniques universitaires Saint-Luc. Planned start Sep 2024; status: authorised.

Drugs

68Ga-UZBRU-VHH2

Conditions

cardiac sarcoidosis (CS)

Beyond the preview

Go deeper on 2024-512473-27-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-512473-27-00.